- BridgeBio Pharma ( NASDAQ: BBIO ) said the first patient was dosed in its phase 1 trial of oral therapy BBP-671 being developed to treat conditions caused by coenzyme A (CoA) deficiencies.
- Coenzyme A plays a role in metabolism via synthesis and oxidation of fatty acids and oxidation of pyruvate in the citric acid cycle.
- The company added that BBP-671 is being developed as a potential therapy for diseases in which CoA metabolism is deficient, including propionic acidemia (PA), methylmalonic acidemia (MMA), and pantothenate kinase-associated neurodegeneration (PKAN).
- The first part of the trial evaluated BBP-671 in healthy people and the second part of the study is evaluating the drug in patients with PA and MMA. Interim data from healthy individuals were reported earlier this year, the company noted in an Aug. 18 press release.
- BridgeBio added that initial data from the second part of the trial is expected in the H1 2023 and it also plans to start a phase 2/3 study in PKAN in 2023.
For further details see:
BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders